Analysis of peripheral neuropathy following treatment with bortezomib in 114 newly-diagnosed multiple myeloma patients
Yafeng CAO,Jing WANG,Jun GU,Hongyu LU,Jie XUN,Yuanfang LIU,Yan WANG,Jin WANG,Yu CHEN,Yubao CHEN,Jiaming LI,Jie HAO,Jianqing MI,Mei CHEN
DOI: https://doi.org/10.16150/j.1671-2870.2017.05.008
2017-01-01
Abstract:Objective:To investigate the occurrence and development of bortezomib-induced peripheral neuropathy in newly-diagnosed multiple myeloma (MM) patients.Methods:A total of 114 newly-diagnosed MM patients receiving bortezomib based therapeutic regimen at Ruijin Hospital,Ruijin Hospital Northern Branch,Shanghai North Station Hospital and Yangpu Hospital from September 2008 to May 2017 were enrolled.According to treatment response,patients were divided into three groups:Group 1,complete remission (CR) and very good partial response (VGPR),60 cases;Group 2,partial remission (PR),20 cases;Group 3,stable disease (SD) and progressive disease (PD),34 cases.The incidence,influencing factors and subsequent improvement of peripheral neuropathy (PN)after 4 treatment cycles were analyzed.Results:The overall incidence of peripheral neuropathy was 65.8％;and there were 49 cases(43.0％) in group 1,13 cases (11.4％) in group 2 and 13 cases (11.4％) in group 3.During the 4 treatment cycles,the dose of bortezomib would be regulated if peripheral neuropathy occurred.Dose of bortezomib was compared between 3 groups by using Kruskal-Wallis test,which revealed that there was significant difference in bortezomib dose and efficacy between the 3 groups (P＜0.05).Efficacy of bortezomib was negatively correlated with peripheral neuropathy.Univariate analysis showed that albumin,beta-2 microglobulin,calcium,hemoglobin,platelets,creatinine,lactate dehydrogenase,sex and age were not the risk factors for peripheral neuropathy (correlation coefficient ＜0.3).Peripheral neuropathy could be ameliorated when patients were given Vitamin B12 (P＜0.05).Conclusions:For newly-daignosed MM patients,the occurrence of PN in the early treatment predicts a better treatment response to bortezomib based therapeutic regimen.Efficacy of bortezomib is negatively correlated with peripheral neuropathy in newly-diagnosed MM patients.The levels of albumin,beta-2 microglobulin,calcium,hemoglobin,platelets,creatinine,lactate dehydrogenase have no correlation with the incidence of peripheral neuropathy.The bortezomib-induced peripheral neuropathy could be reversible with the administration of Vitamin B12.